Neurocrine Biosciences Inc (NBIX)
- Sector
- Biotechnology
- Last price
- $146.38
- As of
Kresmion compiles this page from NBIX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NEUROCRINE BIOSCIENCES INC (NBIX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
See the full NBIX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NBIX on one page. Preview it with sample data, then open it live with a free account.
Preview the NBIX dossierActive events for NBIX
- high13F: funds reduced
3 tracked funds reduced NBIX this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +65% to NBIX (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 99% of NBIX (2026Q2)
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 94% of NBIX (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 175.3%, EPS $2.85 vs $1.0352 estimate
FREE, NO ACCOUNT
Every event on NBIX, as it fires
You are seeing 5 of 13 events recorded on NBIX since 2026-06-09.
The five above landed across 3 days. The other 8 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
NBIX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 64125C109 · 2026Q2 | $393.7M | 0.54% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 64125C109 · 2026Q2 | $349.9M | 0.26% |
| Bridgewater Associates, LP FundCUSIP 64125C109 · 2026Q2 | $34.7M | 0.14% |
| CITADEL ADVISORS LLC FundCUSIP 64125C109 · 2026Q2 | $2M | 0.00% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 64125C109 · 2026Q2 | $2M | 0.00% |
| D. E. Shaw & Co., Inc. FundCUSIP 64125C109 · 2026Q2 | $944K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NBIX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
More data on NBIX
NBIX against its peers
NBIX's operating margin of 21.6% ranks in the 71st percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-01-02.
| Metric | NBIX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.9B USD | 616M USD | 75 | 17 |
| Gross margin | 98.2% | 83.7% | 96 | 13 |
| Operating margin | 21.6% | -6.7% | 71 | 18 |
| Net margin | 16.7% | -19.2% | 66 | 18 |
| Return on equity | 14.7% | -11.8% | 63 | 19 |
| P / E | 31.3x | 27.9x | 50 | 8 |
Peers (23): HALO, BBIO, ASND, EXEL, SMMT, BMRN, INSM, APGE.D, KYMR, CAI, MDGL, BNTX, NUVL.D, PCVX, KRYS, ALNY, IBRX, SYRE, INCY, PTGX, CRNX.D, TGTX, UTHR. Left out: SBMFF (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-01-02. Every figure is one full fiscal year read from one annual filing (NBIX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in NBIX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on NBIX in the last 180 days.
Upstream: SEC EDGAR filings for NBIX
Kresmion, "NEUROCRINE BIOSCIENCES INC (NBIX) institutional holdings and SEC filings", data as of 2026-09-28, https://kresmion.com/research/NBIX. Upstream data: SEC EDGAR filings for NBIX.
Link to this data (HTML):
<a href="https://kresmion.com/research/NBIX">NEUROCRINE BIOSCIENCES INC (NBIX) institutional holdings and SEC filings (Kresmion)</a>
Follow NBIX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to NBIX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.